)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Myriad Genetics
Myriad Genetics (MYGN) investor relations material
Myriad Genetics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 revenue was $202.7M, up 6% QoQ and down 1% YoY; Cancer Care Continuum and Mental Health growth partly offset Prenatal Health declines.
Adjusted EBITDA loss narrowed QoQ to $5.3M from $16.9M; GAAP net loss was $43.9M, versus $27.4M a year earlier.
A planned Prenatal Health sale to Labcorp for $210M plus inventory is intended to sharpen focus on Cancer Care Continuum and improve future growth, profitability and liquidity.
Financial highlights
Q3 gross profit was $137.7M versus $143.8M; operating loss was $39.9M versus $23.3M.
Adjusted net loss was $10.7M, or $0.11 per diluted share; adjusted EBITDA loss was $5.3M, versus $10.3M adjusted EBITDA income in Q3'25.
Adjusted operating expenses rose $9.9M YoY to $149.9M, reflecting strategic investments; sales and marketing expense rose 18% to $83.9M.
Nine-month revenue was $593.8M versus $614.7M; net loss narrowed to $121.2M from $358.0M, which included $316.7M of impairment charges.
Outlook and guidance
FY2026 revenue guidance is $780M-$790M, with the midpoint raised to $785M; Cancer Care Continuum and Mental Health are expected to contribute $620M-$630M.
FY2026 adjusted gross margin guidance remains 66%-67%; Prenatal Health remains in guidance at approximately $160M through its expected early-2027 closing.
In the first 12 months post-close, the Prenatal Health sale is expected to improve revenue growth by 100+ bps and gross margin by 500+ bps.
Sale proceeds may support debt reduction, growth investments and general corporate purposes; no final allocation decision was reported.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Myriad Genetics
- Revenue and ASPs declined, but strategic focus on cancer care and operational initiatives aim to drive recovery.MYGN
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue dropped 11% year-over-year, leading to lower guidance and efficiency actions.MYGNQ2 2026
- All proposals passed, directors elected, and no stockholder questions were raised.MYGNAGM 2026
- Q1 2026 revenue rose 2% to $200.4M, with strong cancer and mental health growth; guidance reaffirmed.MYGNQ1 2026
- 2026 meeting seeks approval for board nominees, auditor, executive pay, and expanded equity plans.MYGNProxy filing
- Shareholders will vote on director elections, auditor ratification, and equity plan approvals.MYGNProxy filing
- Q3 2024 revenue up 11%, but GeneSight faces major payor risk in 2025.MYGNQ3 2024
- Q1 2025 revenue fell 3% year-over-year; 2025 guidance lowered amid GeneSight and hereditary cancer headwinds.MYGNQ1 2025
- 2024 revenue up 11% to $838M, with strong segment growth and reaffirmed 2025 guidance.MYGNQ4 2024
Next Myriad Genetics earnings date
UBS Global Healthcare Conference10 Nov, 2026
Myriad Genetics
Next Myriad Genetics earnings date
UBS Global Healthcare Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Myriad Genetics, Inc. offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.